Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Bought by PFM Health Sciences LP

PFM Health Sciences LP raised its position in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 5.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,306,671 shares of the company’s stock after acquiring an additional 223,299 shares during the quarter. PFM Health Sciences LP owned 4.76% of Caribou Biosciences worth $8,441,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new stake in shares of Caribou Biosciences during the second quarter worth approximately $2,432,000. Vanguard Group Inc. grew its position in shares of Caribou Biosciences by 3.8% during the first quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company’s stock worth $21,129,000 after buying an additional 148,751 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Caribou Biosciences by 25.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after buying an additional 536,162 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Caribou Biosciences by 103.5% during the third quarter. Exchange Traded Concepts LLC now owns 82,494 shares of the company’s stock worth $162,000 after buying an additional 41,948 shares in the last quarter. Finally, Walleye Trading LLC acquired a new stake in shares of Caribou Biosciences during the first quarter worth approximately $155,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Stock Performance

CRBU stock opened at $2.19 on Friday. The stock has a market capitalization of $198.30 million, a price-to-earnings ratio of -1.33 and a beta of 2.26. Caribou Biosciences, Inc. has a 1 year low of $1.50 and a 1 year high of $8.33. The stock’s fifty day moving average is $2.05 and its two-hundred day moving average is $2.14.

Caribou Biosciences (NASDAQ:CRBU) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. The company had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, analysts predict that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on CRBU. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Caribou Biosciences in a report on Wednesday, August 7th. Citigroup decreased their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a report on Friday, November 15th. Four investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences has an average rating of “Buy” and a consensus target price of $10.20.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.